LeMaitre Vascular Sees Q2 EPS $0.45-$0.50 vs $0.44 Est., Sales $53.7M-$56.1M vs $54.29M Est.; Sees FY24 EPS $1.73-$1.84 vs $1.65 Est., Sales $212.7M-$217.3M vs $211.7M Est.
Portfolio Pulse from Benzinga Newsdesk
LeMaitre Vascular forecasts Q2 EPS of $0.45-$0.50, surpassing the $0.44 estimate, with sales between $53.7M-$56.1M, also above the $54.29M estimate. For FY24, the company expects EPS of $1.73-$1.84, exceeding the $1.65 estimate, and sales of $212.7M-$217.3M, surpassing the $211.7M estimate.
May 02, 2024 | 9:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LeMaitre Vascular projects higher than expected Q2 and FY24 earnings and sales, indicating strong financial health and potential market growth.
LeMaitre Vascular's projection of higher than expected earnings and sales for both Q2 and FY24 suggests a positive outlook for the company's financial performance. This is likely to instill confidence among investors, potentially leading to an increase in stock price in the short term. The company's ability to surpass analysts' estimates indicates strong operational efficiency and market demand for its products, which are key drivers for stock performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100